Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma

European Journal of Cancer

Volumn 49, Issue 13, 2013, Pages 2841-2850

  Fishman, M N ^a   Srinivas, S ^b   Hauke, R J ^c   Amato, R J ^d   Esteves, B ^e   Cotreau, M M ^e   Strahs, A L ^e   Slichenmyer, W J ^e   Bhargava, P ^e,f   Kabbinavar, F F ^g  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c Nebraska Cancer Specialists   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e AVEO ONCOLOGY   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dose escalation; Maximum tolerated dose; Pharmacokinetics; Renal cell carcinoma; Temsirolimus; Tivozanib

Indexed keywords

RAPAMYCIN; TEMSIROLIMUS; TIVOZANIB; VASCULOTROPIN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD SAMPLING; CANCER PATIENT; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSGEUSIA; DYSPHONIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FEVER; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; HYPERMAGNESEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INSOMNIA; KIDNEY CARCINOMA; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; SKIN; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; VOMITING;

DOSE ESCALATION; MAXIMUM TOLERATED DOSE; PHARMACOKINETICS; RENAL CELL CARCINOMA; TEMSIROLIMUS; TIVOZANIB;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; QUINOLINES; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84881094547     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.04.019     Document Type: Article

References (36)

1. B.I. Rini Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma Cancer 115 2009 2306 2312
2. G.R. Hudes Targeting mTOR in renal cell carcinoma Cancer 115 2009 2313 2320
3. P. Mulders Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms BJU Int 104 2009 1585 1589
4. J. Sosman, and I. Puzanov Combination targeted therapy in advanced renal cell carcinoma Cancer 115 2009 2368 2375
5. P.H. Patel, P.L. Senico, R.E. Curiel, and R.J. Motzer Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma Clin Genitourin Cancer 7 2009 24 27
6. A.M. Molina, D.R. Feldman, and M.H. Voss Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma Cancer 118 2012 1868 1876
7. D.M. Waterhouse, W.C. Penley, and C.D. Webb Sorafenib and everolimus (RAD001) in the treatment of patients with advanced clear cell renal carcinoma (RCC): a Sarah Cannon Research Institute phase I/II trial J Clin Oncol 29 2011 4629
8. J.D. Hainsworth, D.R. Spigel, and H.A. Burris III Waterhouse D, Clark BL, Whorf R. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma J Clin Oncol 28 2010 2131 2136
9. J.R. Merchan, H.C. Pitot, and R. Qin Final phase II safety and efficacy results of study MC0452: phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma J Clin Oncol 29 2011 Abstract 4548
10. S. Negrier, G. Gravis, and D. Perol Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial Lancet Oncol 12 2011 673 680
11. Flaherty K. E2804 The BeST trial: a randomized phase II study of VEGF, RAF kinase and mTOR combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell cancer. In: The 11th International Kidney Cancer Symposium (Chicago, IL); October 5-6, 2012.
12. K. Nakamura, E. Taguchi, and T. Miura KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties Cancer Res 66 2006 9134 9142
13. P. Bhargava, and M.O. Robinson Development of second-generation VEGFR tyrosine kinase inhibitors: current status Curr Oncol Rep 13 2011 103 111
14. R. Kumar, M.C. Crouthamel, and D.H. Rominger Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors Br J Cancer 101 2009 1717 1723
15. D.D. Hu-Lowe, H.Y. Zou, and M.L. Grazzini Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3 Clin Cancer Res 14 2008 7272 7283
16. Eskens FALM, De Jonge MJA, Esteves B, et al. Updated results from a phase I study of AV-951 (KRN951), a potent and selective VEGFR-1, -2 and -3 tyrosine kinase inhibitor, in patients with advanced solid tumors. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (San Diego, CA); April 12-16, 2008. Abstract LB-201.
17. H. Hurwitz, A. Dowlati, and S. Savage Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors J Clin Oncol 23 2005 195s Abstract 3012
18. NEXAVAR (sorafenib) tablets, oral [package insert]. Wayne (NJ): Bayer Healthcare Pharmaceuticals Inc.; 2010.
19. H.S. Rugo, R.S. Herbst, and G. Liu Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results J Clin Oncol 23 2005 5474 5483
20. SUTENT® (sunitinib malate) capsules, oral [package insert]. New York (NY): Pfizer Inc; 2011.
21. D.A. Nosov, B. Esteves, and O.N. Lipatov Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma J Clin Oncol 30 2012 1678 1685
22. AVEO Pharmaceuticals Inc. AVEO and Astellas announce tivozanib successfully demonstrated progression-free survival superiority over sorafenib in patients with advanced renal cell cancer in phase 3 TIVO-1 trial. Available at: http://investor.aveopharma.com/phoenix.zhtml?c=219651&p=irol- newsArticle&ID=1643913&highlight=; 2012 [accessed February 10, 2012].
23. T. Fuereder, A. Jaeger-Lansky, and D. Hoeflmayer mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo Cancer Lett 296 2010 249 256
24. A. Patnaik, S.G. Eckhardt, and E. Izbicka A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies Clin Cancer Res 9 2003 4761 4771
25. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
26. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
27. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
28. B.I. Rini, B. Escudier, and P. Tomczak Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 278 2011 1931 1939
29. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
30. Eskens FALM, Oldenhuis CNAM, Bhargava P, et al. A phase 1b study of escalating doses of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor tivozanib and FOLFOX6 in patients with advanced gastrointestinal (GI) tumors. In: Poster presented at: the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics (Berlin, Germany); November 16-19, 2010. Poster PP19.
31. M.B. Atkins, M. Hidalgo, and W.M. Stadler Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 22 2004 909 918
32. R.J. Motzer, G.R. Hudes, and B.D. Curti Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma J Clin Oncol 25 2007 3958 3964
33. TORISEL® (temsirolimus) injection [prescribing information]. Philadelphia (PA): Wyeth Pharmaceuticals Inc.; 2008.
34. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
35. Rini BI, Bellmunt J, Clancy J, et al. Randomized phase IIIb trial of temsirolimus and bevacizumab versus interferon and bevacizumab in metastatic renal cell carcinoma: results from INTORACT. In: The Annual Meeting of the European Society for Medical Oncology (ESMO) (Vienna, Austria); September 28-October 2, 2012. Abstract LBA21-PR.
36. Ravaud A, Barrios C, Anak O, et al. Randomized phase II study of first-line everolimus (EVE) + bevacizumab (BEV) versus interferon alfa-2A (IFN) + BEV in patients (pts) with metastatic renal cell carcinoma (MRCC): RECORD-2. In: The Annual Meeting of the European Society for Medical Oncology (ESMO) (Vienna, Austria); September 28-October 2, 2012. Abstract 7830.